Johnson & Johnson group Janssen Biotech has hooked up with Aduro BioTech again, this time to develop treatments for lung cancer immunptherapies.

The alliance sees Janssen bag an exclusive, global license to certain product candidates engineered for the treatment of lung cancer based on Aduro’s novel LADD* immunotherapy platform, following an agreement earlier this year centred on new immunotherapies for prostate cancer.

As per the terms of the deal, facilitated by the J&J Innovation Center, Aduro stands to receive a $30 million up-front fee, development, regulatory and commercialisation milestones worth up to $817 million, as well as high single-digit to double-digit tiered royalties on worldwide net sales of any marketed products.

Janssen will take responsibility for all research, development, manufacturing, regulatory and commercialisation activities for any successful candidates.

*LADD is a platform of live-attenuated double-deleted Listeria monocytogenes strains altered to spark a potent innate immune response and to express tumour-associated antigens to induce tumour-specific T cell-mediated immunity.